Overview of Clinical Outcome and Therapeutic Effectiveness of Favipiravir in Patients with COVID-19 Admitted to Intensive Care Unit, Riyadh, Saudi Arabia

Al Mutair et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.01.013

Feb 2022

Retrospective 269 favipiravir ICU patients in Saudi Arabia and 269 matched controls receiving different treatments, showing no significant difference.

This study is excluded in the after exclusion results of meta analysis: very late stage, ICU patients.

Important missing comments or errors? Let us know.

risk of death, 7.0% lower, RR 0.93, p = 0.49, treatment 119 of 269 (44.2%), control 128 of 269 (47.6%), NNT 30.

risk of ARDS, 8.6% higher, RR 1.09, p = 0.63, treatment 76 of 269 (28.3%), control 70 of 269 (26.0%), severe ARDS.

ICU time, 33.7% higher, relative time 1.34, p = 0.001, treatment 269, control 269.

hospitalization time, 36.6% higher, relative time 1.37, p = 0.001, treatment 269, control 269.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Al Mutair et al., 15 Feb 2022, retrospective, Saudi Arabia, peer-reviewed, 14 authors, study period April 2020 - March 2021, this trial compares with another treatment - results may be better when compared to placebo.

This Paper Favipiravir All

Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia

Abbas Al Mutair, Jinan Shamou, Saad Alhumaid, Laila Layqah, Gasmelseed Y Ahmed, Koritala Thoyaja, Mohammed Al Mohaini, Sana Almahmoud, Mazin Barry, Amjad Khan, Kuldeep Dhama, Lamiaa Hamad Al-Jamea, Alxeander Woodman, Ali A Rabaan

Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.01.013

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

Al-Wathinani, Increased Emergency Calls during the COVID-19 Pandemic in Saudi Arabia: A National Retrospective Study, Healthcare, doi:10.3390/healthcare9010014

Alharthy, Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study, Journal of epidemiology and global health, doi:10.2991/jegh.k.200928.001

Almoosa, Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study, J Infect Public Health, doi:10.1016/j.jiph.2021.08.022

Alsofayan, Althunayyan, Khan, Hakawi, Assiri, Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective study, Journal of infection and public health, doi:10.1016/j.jiph.2020.05.026

Argenziano, Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series, Bmj, doi:10.1136/bmj.m1996

Bai, Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014, Clin Infect Dis, doi:10.1093/cid/ciw571

Bartoletti, Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, doi:10.1016/j.cmi.2020.09.014

Beigel, Remdesivir for the Treatment of Covid-19 -Final Report, The New England journal of medicine, doi:10.1056/NEJMoa2007764

Bosaeed, Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19, BMJ Open, doi:10.1136/bmjopen-2020-047495

Cai, Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering, doi:10.1016/j.eng.2020.03.007

Cao, A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282

Chen, Chao, Lai, Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients, The Journal of infection, doi:10.1016/j.jinf.2020.12.005

Chen, Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial, medRxiv, doi:10.1101/2020.03.17.20037432

Choy, Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104786

Chu, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax, doi:10.1136/thorax.2003.012658

Cummings, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet, doi:10.1016/S0140-6736(20)31189-2

Delang, Abdelnabi, Neyts, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses, Antiviral Res, doi:10.1016/j.antiviral.2018.03.003

Fiolet, Guihur, Rebeaud, Mulot, Peiffer-Smadja et al., Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, doi:10.1016/j.cmi.2020.08.022

Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proceedings of the Japan Academy. Series B, Physical and biological sciences, doi:10.2183/pjab.93.027

Gavriatopoulou, Emerging treatment strategies for COVID-19 infection, Clinical and experimental medicine, doi:10.1007/s10238-020-00671-y

Guan, Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032

Horby, Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2021436

Hu, Risk Factors Associated With Clinical Outcomes in 323 Coronavirus Disease 2019 (COVID-19) Hospitalized Patients in Wuhan, China, Clin Infect Dis, doi:10.1093/cid/ciaa539

Huang, Pranata, Lim, Oehadian, Alisjahbana, C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis, Therapeutic advances in respiratory disease, doi:10.1177/1753466620937175

J O U R N, a l P r e -p r o o f international review of thoracic diseases, doi:10.1159/000507940

Khamis, Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.008

Khorram-Manesh, Goniewicz, Hertelendy, Dulebenets, Handbook of Disaster and Emergency Management

Ko, Arguments in favour of remdesivir for treating SARS-CoV-2 infections, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105933

Kocayiğit, Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19, Journal of Clinical Pharmacy and Therapeutics

Koritala, A narrative review of emergency use authorization versus full FDA approval and its effect on COVID-19 vaccination hesitancy

Liang, A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir, European journal of medicinal chemistry, doi:10.1016/j.ejmech.2020.112527

Lighter, Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission, Clin Infect Dis

Liu, Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Sci China Life Sci, doi:10.1007/s11427-020-1643-8

Liu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0

Mahévas, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, Bmj

Mortaz, Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra, International immunopharmacology, doi:10.1016/j.intimp.2021.107407

Oestereich, Lüdtke, Wurr, Rieger, Muñoz-Fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res, doi:10.1016/j.antiviral.2014.02.014

Perazzolo, Zhu, Lin, Nguyen, Ho, Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective, J Pharm Sci, doi:10.1016/j.xphs.2020.11.019

Prompetchara, Ketloy, Palaga, Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic, Asian Pac J Allergy Immunol, doi:10.12932/ap-200220-0772

Qin, Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19), Clin Infect Dis, doi:10.1093/cid/ciaa248

Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis, Virol J, doi:10.1186/s12985-020-01412-z

Sinha, Balayla, Hydroxychloroquine and COVID-19, Postgraduate Medical Journal, doi:10.1136/postgradmedj-2020-137785

Solaymani-Dodaran, Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia, International immunopharmacology, doi:10.1016/j.intimp.2021.107522

Totura, Bavari, Broad-spectrum coronavirus antiviral drug discovery, Expert opinion on drug discovery, doi:10.1080/17460441.2019.1581171

Van Eeden, Hogg, Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies, Respiration, doi:10.1159/000502261

Vidali, D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review, ERJ Open Res, doi:10.1183/23120541.00260-2020

Wang, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, Jama, doi:10.1001/jama.2020.1585

Wang, Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report, Annals of internal medicine, doi:10.7326/L20-0354

Wang, Zhou, Yang, Xia, Hu et al., Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in

Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, Jama, doi:10.1001/jama.2020.2648

Wu, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern Med, doi:10.1001/jamainternmed.2020.0994

Xiong, Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study, BMC infectious diseases, doi:10.1186/s12879-020-05452-2

Yang, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, doi:10.1016/s2213-2600(20)30079-5

Ye, Wang, Mao, The pathogenesis and treatment of the `Cytokine Storm' in COVID-19, J Infect, doi:10.1016/j.jinf.2020.03.037

Yu, Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis, J Thromb Thrombolysis, doi:10.1007/s11239-020-02171-y

Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/s0140-6736(20)30566-3

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0